Condition: LIPOPROTEIN GLOMERULOPATHY


rs121918397 in APOE gene and LIPOPROTEIN GLOMERULOPATHY PMID 9176854 1997 Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.

PMID 10432380 1999 Lipoprotein glomerulopathy (LPG) is characterized by intraglomerular lipoprotein thrombosis and high plasma concentrations of apolipoprotein (apo) E. An apo E variant, apo E2 (Arg145Pro) Sendai, was recently identified in three patients with LPG.

PMID 10903326 2000 Recent studies identified several apoE mutations in patients with LPG, including apoE2(R145P) Sendai (apoE-Sendai).

PMID 18077821 2007 APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy.

PMID 10903326 2000 Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.

PMID 9176854 1997 Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.

PMID 10432380 1999 Apo E2 (Arg25Cys) Kyoto is a novel mutation of apo E that is etiologically related to LPG.